Literature DB >> 25818594

Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond.

Sally B Rose1, Susan M Garrett2, James Stanley3.   

Abstract

OBJECTIVES: The aims of this study were to compare immediate postabortion uptake of recently subsidized (no-cost) levonorgestrel-releasing implants with already available intrauterine and shorter-acting methods and to compare the incidence of subsequent pregnancies (ending in birth or abortion) within 2 years. STUDY
DESIGN: Retrospective chart review of 4698 women attending a New Zealand public hospital abortion clinic over 2 years (2010-2012) to describe postabortion contraceptive choice, with follow-up via clinic and national births records to assess subsequent pregnancies at 12, 24, 36, and 48 months.
RESULTS: Twenty percent of the cohort (934/4698) received an implant, 26% an intrauterine method (927 copper intrauterine device, 301 levonorgestrel-releasing intrauterine system [LNG-IUS]), and 54% chose other shorter-acting methods (2536/4698). Method choice was significantly associated with age, ethnicity, and pregnancy history (p < .001). At 24 months, the unadjusted incidence of subsequent abortion for implant users was 3.8% (95% confidence interval [CI] = 2.5-5.0) and 11.6% (95% CI = 10.3-12.8) for those choosing other short-acting methods. By 48 months, 6.6% of implant users had a subsequent abortion (compared with 18.3% for short-acting methods). The incidence of continued pregnancy at 24 months was 6.3% (95% CI = 4.4-8.1) for implant users and 15.7% (95% CI = 14-17.2) for those choosing other short-acting methods. Adjusted hazard ratios (HRs) for subsequent abortion were lowest for women initiating an implant (HR = 0.26, 95% CI = 0.20-0.35) or LNG-IUS (HR = 0.26, 0.16-0.44, reference group: short-acting methods).
CONCLUSIONS: Immediate postabortion insertion of an implant significantly reduced rates of subsequent pregnancy for at least 2 years. Abortion service providers should ensure women have barrier-free access to all long-acting reversible contraceptions to delay or prevent pregnancy. IMPLICATIONS: Initiation of an levonorgestrel implant immediately postabortion was associated with a 74% reduction in subsequent abortion over the next 4 years compared with use of short-acting methods. Implants were popular among adolescents-a group at high-risk of subsequent pregnancy, and who have not historically been considered appropriate candidates for intrauterine contraceptive methods.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Copper multiload Cu375 intrauterine device; Levonorgestrel intrauterine system; Levonorgestrel-releasing subdermal implant; Long-acting reversible contraception (LARC); Unintended pregnancy

Mesh:

Substances:

Year:  2015        PMID: 25818594     DOI: 10.1016/j.contraception.2015.03.012

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  4 in total

1.  Postabortion long-acting reversible contraception desire in women counselled using Bedsider.org versus standard counselling: a randomised trial.

Authors:  Sarita Sonalkar; Jessica McClusky; Rachna Vanjani; Olivera Vragovic; Mary D Sammel; Lynn Borgatta
Journal:  BMJ Sex Reprod Health       Date:  2018-05-30

Review 2.  Immediate versus delayed postabortal insertion of contraceptive implant.

Authors:  Jen Sothornwit; Nuntasiri Eamudomkarn; Pisake Lumbiganon; Nampet Jampathong; Mario R Festin; Lingling Salang
Journal:  Cochrane Database Syst Rev       Date:  2022-05-18

3.  Contraception after Abortion and Risk of Repeated Unintended Pregnancy among Health Plan Members.

Authors:  Debbie Postlethwaite; Justine Lee; Maqdooda Merchant; Amy Alabaster; Tina Raine-Bennett
Journal:  Perm J       Date:  2018

4.  Specialist follow-up contraceptive support after abortion-Impact on effective contraceptive use at six months and subsequent abortions: A randomised controlled trial.

Authors:  Usha Kumar; Louise Pollard; Lucy Campbell; Selin Yurdakul; Clara Cantalapiedra Calvete; Bola Coker; Tao Chen; Abdel Douiri
Journal:  PLoS One       Date:  2019-06-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.